A Phase 1/2a Multi-Center Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Evidence of Antitumor Activity of JAB-3312 in combination with pembrolizumab or binimetinib in Adult Patients with Advanced Solid Tumors

Brief description of study

The purpose of the study is to determine and demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 or MEKi in patients with advanced solid tumors. We also want to determine the recommended phase 2 dose (RP2D) of JAB-3312 in combination with pembrolizumab or binimetinib in patients with advanced solid tumors. The study drug JAB-3312 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.